Thursday, March 16, 2017 4:30:03 PM
'Pursuant to the Collaboration Agreement, we are responsible for completing the three ENCORE trials and the POLT-HCV-SVR trial described above . Prior to Novartis’ exercise of the option, Novartis will reimburse us for any costs of the se four Phase 2 b t rials that exceed an agreed upon budget or we will credit any amount under budget to Novartis’ future costs for the four Phase 2 b t rials. If Novartis exercises its option, we will share the costs of the se four Phase 2 b trials equally with Novartis after the effective date of the license grant under the Collaboration Agreem ent . Novartis will also be responsible for 100% of certain expenses for required registration-supportive nonclinical activities . Novartis will be responsible for the development of emricasan beyond the four Phase 2 b trials described above , including the Ph ase 3 development of emricasan single agent products and all development for emricasan combination products , and Novartis has agreed to use commercially reasonable efforts to develop and commercialize emricasan products , if the option is exercised . A joint steering committee comprised of representatives from our company and Novartis will oversee the collaboration, development and commercialization of emricasan products.'
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM